Novo Nordisk A/S reports results for the quarter ended June 30 - Earnings Summary

• Novo Nordisk A/S NOVOb.CO reported quarterly adjusted earnings of DKK5.96​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of DKK4.49. The mean expectation of twelve analysts for the quarter was for earnings of DKK5.97 per share. Wall Street expected results to range from DKK5.72 to DKK6.26 per share.

• Revenue rose 12.9% to DKK76.86 billion from a year ago; analysts expected DKK76.55 billion.

• Novo Nordisk A/S's reported EPS for the quarter was DKK5.96​.

• The company reported quarterly net income of DKK26.5 billion.

• Novo Nordisk A/S shares had fallen by 30.4% this quarter and lost 51.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 4.4% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 13 "strong buy" or "buy," 12 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Novo Nordisk A/S is DKK500.00, about 38.8% above its last closing price of DKK305.90

This summary was machine generated from LSEG data August 6 at 09:36 a.m. UTC. ​All figures in Danish crowns unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)